Glycoconjugate vaccine for leishmaniasis

US11224645B2 · kind B2 · utility

Assignee

• The Board of Regents of the University of Texas System · US

Inventors

• Rosa A. Maldonado · El Paso, US
• Igor Almeida · Indaiatuba, BR
• Katja Michael · El Paso, US
• Eva Adriana Iniguez · El Paso, US

Key dates

• Filing date: Mar 22, 2016
• Grant date: Jan 18, 2022
• Expiry date: Jun 28, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Certain embodiments are directed to an immunogenic composition comprising an immunogenic glycoconjugate comprising a glycan having the chemical formula of galactopyranose (Galp)-α(1,2)-R, Galp-α(1,3)-R, Galp-α(1,4)-R, or Galp-α(1,6)-R, wherein in R is any monosaccharide, oligosaccharide, or polysaccharide, coupled to a carrier peptide or protein. Certain aspects described herein are directed to compounds and therapies for treating Leishmania infections. In certain aspects, the glycoconjugates as described herein, are incorporated into pharmaceutical compositions or vaccines